Posted by Michael Wonder on 28 Mar 2022
Xenpozyme (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
28 March 2022 - Xenpozyme represents first Sanofi therapy to be approved under the SAKIGAKE ‘fast-track’ designation.
The Japanese MHLW has granted marketing authorisation for Xenpozyme (olipudase alfa) for the treatment of adult and paediatric patients with non-central nervous system manifestations of acid sphingomyelinase deficiency, a rare, progressive, and potentially life-threatening genetic disease.
